Hemogenyx Pharmaceuticals PLC Working Capital to Net Assets Ratio
Hemogenyx Pharmaceuticals PLC working capital to net assets ratio. Hemogenyx Pharmaceuticals PLC (HEMO) has a Working Capital to Net Assets ratio of 137.8% as of June 2025. Working capital of GBX-752.98K (current assets of GBX569.81K minus current liabilities of GBX1.32 Million) is measured against net assets of GBX-546.41K. A higher ratio indicates strong short-term liquidity financed by the equity base. Check HEMO goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Hemogenyx Pharmaceuticals PLC (2015–2024)
Working capital to net assets ratio of Hemogenyx Pharmaceuticals PLC from 2015 to 2024. This chart shows how Hemogenyx Pharmaceuticals PLC's Working Capital to Net Assets ratio has evolved across 10 annual periods from 2015 to 2024. As of June 2025, the ratio stands at 137.8%, reflecting working capital of GBX-752.98K against net assets of GBX-546.41K GBX. See Hemogenyx Pharmaceuticals PLC (HEMO) defensive interval to measure how many days the company can operate on defensive assets alone.
Hemogenyx Pharmaceuticals PLC Working Capital to Net Assets Ratio by Year (2015–2024)
Hemogenyx Pharmaceuticals PLC working capital to net assets ratio by year from 2015 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for Hemogenyx Pharmaceuticals PLC from 2015 to 2024, covering 10 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see HEMO current and non-current assets.
| Year | WC/NA Ratio | Working Capital (GBX) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | -37.4% | GBX-319.61K | GBX853.49K | GBX839.05K | GBX1.16 Million | ▼ -92.0 pp |
| 2023 | 54.6% | GBX1.52 Million | GBX2.78 Million | GBX2.17 Million | GBX652.09K | ▼ -2.4 pp |
| 2022 | 56.9% | GBX1.85 Million | GBX3.24 Million | GBX2.59 Million | GBX748.41K | ▼ -26.2 pp |
| 2021 | 83.1% | GBX6.79 Million | GBX8.17 Million | GBX7.14 Million | GBX352.84K | ▲ +67.3 pp |
| 2020 | 15.8% | GBX138.40K | GBX875.68K | GBX1.92 Million | GBX1.78 Million | ▲ +122.6 pp |
| 2019 | -106.8% | GBX372.91K | GBX-349.04K | GBX554.48K | GBX181.57K | ▼ -282.5 pp |
| 2018 | 175.7% | GBX1.69 Million | GBX959.17K | GBX1.85 Million | GBX167.61K | ▲ +96.8 pp |
| 2017 | 78.9% | GBX1.68 Million | GBX2.13 Million | GBX1.95 Million | GBX263.69K | ▼ -21.1 pp |
| 2016 | 100.0% | GBX903.71K | GBX903.71K | GBX1.05 Million | GBX143.69K | ▲ +6.5 pp |
| 2015 | 93.5% | GBX72.73K | GBX77.82K | GBX89.01K | GBX16.28K | — |